TICKERNERD
Menu
TDACTDACFinancial Services · Shell Companies

TDAC Stock Forecast: Translational Development Acquisition Corp. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$11
0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$209.1M
Ticker Nerd rank
48 / 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
+0.8%
1M
+1.1%
YTD
+3.2%
1Y
+4.6%
From 52W high
−0.1%
From 52W low
+5.0%
$10
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TDAC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Translational Development Acquisition Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
95
Value
85
Momentum
79
Size
65
Quality
60
Issuance
38
Accruals
32
Revisions
25
Growth
16

Volatility (95): The share price has been relatively steady.

Growth (16): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Translational Development Acquisition Corp. — and when they’d sell — is the membership.

Wall Street

TDAC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TDAC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$10$11$11$11$11$11Oct 25Jan 26Apr 26Jul 26TDAC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Sept 2021Northland Capital MarketsInitiatesOutperform$16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TDAC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Translational Development Acquisition Corp. (TDAC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
38.7×

Cheaper than 21% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 61% of US stocks

EV / EBITDA
−28.8×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−10.1%

Higher than 26% of US stocks

Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
3.6%

Higher than 51% of US stocks

Return on assets
−0.3%

Higher than 42% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TDAC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelShell Companies
CompanyMarket capTKN rank
TDACTranslational Development Acquisition Corp.$209.1M
48
TDWDTailwind 2.0 Acquisition Corp.$236.4M
17
MACIMelar Acquisition Corp. I$236.1M
45
TWLVTwelve Seas Investment Co. III$234.6M
24
DYNCDynamix Corp. (Cayman Islands)$240.1M
44
SSACSPACSphere Acquisition Corp.$233.7M
17
MCGAYorkville Acquisition Corp.$241.2M
21
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TDAC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TDAC news & analysis

ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

GlobeNewsWire · 28 July 2026positive

ProLogium and Translational Development Acquisition Corp. announced a $50 million primary capital investment commitment from existing ProLogium shareholders to support their previously announced business combination.

Why it matters — The committed capital investment strengthens the financial backing for TDAC's proposed merger with ProLogium, moving the deal closer to completion.

FAQ

Frequently asked questions about TDAC stock

How does Ticker Nerd's model rank TDAC?

As at 1 Aug 2026, Translational Development Acquisition Corp. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (95 of 100).

What is the TDAC stock forecast for 2030?

No analyst covering Translational Development Acquisition Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TDAC are extrapolating price history, which says nothing about the business.

How has TDAC stock performed over the past year?

Translational Development Acquisition Corp. returned +4.6% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Translational Development Acquisition Corp. do?

Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with businesses in the biopharmaceutical and pharmaceutical industry sectors.

What is the latest news on TDAC?

The most recent item we track (GlobeNewsWire, 28 July 2026): "ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination". ProLogium and Translational Development Acquisition Corp. announced a $50 million primary capital investment commitment from existing ProLogium shareholders to support their previously announced business combination.

Company

About Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a special purpose acquisition company (SPAC) focused on identifying and merging with businesses in the biopharmaceutical and pharmaceutical industry sectors. Aiming to leverage and support the growth of novel life sciences enterprises, this SPAC is dedicated to facilitating strategic partnerships that can lead to innovation and advancement in drug development and healthcare solutions. Translational Development Acquisition Corp. primarily targets companies with promising research and development pipelines that have the potential to transform patient care and enhance therapeutic options. This acquisition entity plays a pivotal role in providing capital and market access for rising enterprises within the dynamic and evolving field of biotechnology and pharmaceuticals, emphasizing the importance of scientific progress and industry collaboration in addressing unmet medical needs.

CEO Mr. Michael M. B. Hoffman J.D. · United States · https://www.translational-development.com